García-Martínez Carolina, Fernández-Carvajal Asia, Valenzuela Belen, Gomis Ana, Van Den Nest Wim, Ferroni Stefano, Carreño Cristina, Belmonte Carlos, Ferrer-Montiel Antonio
Instituto de Biología Molecular y Celular, Universidad Miguel Hernández, Alicante, Spain.
J Pain. 2006 Oct;7(10):735-46. doi: 10.1016/j.jpain.2006.03.008.
Vanilloid receptor subunit 1 (TRPV1) is an integrator of physical and chemical stimuli in the peripheral nervous system. This receptor plays a key role in the pathophysiology of inflammatory pain. Thus, the identification of receptor antagonists with analgesic and anti-inflammatory activity in vivo is an important goal of current neuropharmacology. Here, we report that [L-arginyl]-[N-[2,4-dichlorophenethyl]glycyl]-N-(2,4-dichlorophenethyl) glycinamide (H-Arg-15-15C) is a channel blocker that abrogates capsaicin and pH-evoked TRPV1 channel activity with submicromolar activity. Compound H-Arg-15-15C preferentially inhibits TRPV1, showing marginal block of other neuronal receptors. Compound H-Arg-15-15C acts as a noncompetitive capsaicin antagonist with modest voltage-dependent blockade activity. The compound inhibited capsaicin-evoked nerve activity in afferent fibers without affecting mechanically activated activity. Notably, administration of compound H-Arg-15-15C prevented the irritant activity of a local administration of capsaicin and formalin and reversed the thermal hyperalgesia evoked by injection of complete Freund's adjuvant. Furthermore, it attenuated carrageenan-induced paw inflammation. Compound H-Arg-15-15C specifically decreased inflammatory conditions without affecting normal nociception. Taken together, these findings demonstrate that compound H-Arg-15-15C is a channel blocker of TRPV1 with analgesic and anti-inflammatory activity in vivo at clinically useful doses and substantiate the tenet that TRPV1 plays an important role in the etiology of chronic inflammatory pain.
This study reports the design of a potent TRPV1 noncompetitive antagonist that exhibits anti-inflammatory and analgesic activity in preclinical models of acute and chronic pain. This compound is a lead for analgesic drug development.
香草酸受体亚基1(TRPV1)是外周神经系统中物理和化学刺激的整合者。该受体在炎性疼痛的病理生理学中起关键作用。因此,鉴定在体内具有镇痛和抗炎活性的受体拮抗剂是当前神经药理学的一个重要目标。在此,我们报告[L-精氨酰]-[N-[2,4-二氯苯乙基]甘氨酰]-N-(2,4-二氯苯乙基)甘氨酰胺(H-Arg-15-15C)是一种通道阻滞剂,它能以亚微摩尔活性消除辣椒素和pH值诱发的TRPV1通道活性。化合物H-Arg-15-15C优先抑制TRPV1,对其他神经元受体的阻断作用微弱。化合物H-Arg-15-15C作为一种非竞争性辣椒素拮抗剂,具有适度的电压依赖性阻断活性。该化合物抑制辣椒素诱发的传入纤维神经活动,而不影响机械激活的活动。值得注意的是,给予化合物H-Arg-15-15C可预防局部注射辣椒素和福尔马林的刺激活性,并逆转注射完全弗氏佐剂诱发 的热痛觉过敏。此外,它减轻了角叉菜胶诱导的爪部炎症。化合物H-Arg-15-15C特异性地减轻炎症状态,而不影响正常的痛觉感受。综上所述,这些发现表明化合物H-Arg-15-15C是一种TRPV1通道阻滞剂,在临床可用剂量下在体内具有镇痛和抗炎活性,并证实了TRPV1在慢性炎性疼痛病因中起重要作用这一观点。
本研究报告了一种有效的TRPV1非竞争性拮抗剂的设计,该拮抗剂在急性和慢性疼痛的临床前模型中表现出抗炎和镇痛活性。该化合物是镇痛药开发的先导物。